Adrenocortical carcinoma cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{Adrenocortical carcinoma}} | {{Adrenocortical carcinoma}} | ||
Patients should be followed in 3-month intervals after initial treatment for 2 to 3 years. | |||
After that, surveillance intervals be increased to 6 monthsfor the coming 5 years. | |||
Surveillance should also include: (95) | |||
* Cross-sectional imaging of chest, abdomen, and pelvis for resaging | |||
* The use of FDG-PET for lesions of an unclear nature | |||
* Laboratory evaluation for steroid hormones | |||
* Evaluation for side effects is also important in case of adjuvant mitotane therapy | |||
==References== | ==References== |
Revision as of 19:14, 21 September 2017
Adrenocortical carcinoma Microchapters |
Differentiating Adrenocortical carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Study |
Adrenocortical carcinoma cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Adrenocortical carcinoma cost-effectiveness of therapy |
FDA on Adrenocortical carcinoma cost-effectiveness of therapy |
CDC on Adrenocortical carcinoma cost-effectiveness of therapy |
Adrenocortical carcinoma cost-effectiveness of therapy in the news |
Blogs on Adrenocortical carcinoma cost-effectiveness of therapy |
Risk calculators and risk factors for Adrenocortical carcinoma cost-effectiveness of therapy |
Patients should be followed in 3-month intervals after initial treatment for 2 to 3 years.
After that, surveillance intervals be increased to 6 monthsfor the coming 5 years.
Surveillance should also include: (95)
- Cross-sectional imaging of chest, abdomen, and pelvis for resaging
- The use of FDG-PET for lesions of an unclear nature
- Laboratory evaluation for steroid hormones
- Evaluation for side effects is also important in case of adjuvant mitotane therapy